Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goserelin 3.6 mg one‑month implant in prostate cancer
2011-001193-26Phase 3Completed
- Sponsor
- Acino
- Start
- Aug 2011
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of goserelin in prostate cancer (PCa) (2 arms), sponsored by Acino. Primary endpoint: Testosterone response rate. Started Aug 2011; status: completed.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2011-001193-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001193-26.